Zhong L - Search Results

1

11,11'-dideoxy-verticillin: a natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity.

Zhang YX, Chen Y, Guo XN, Zhang XW, Zhao WM, Zhong L, Zhou J, Xi Y, Lin LP, Ding J. Zhang YX, et al. Among authors: zhong l. Anticancer Drugs. 2005 Jun;16(5):515-24. doi: 10.1097/00001813-200506000-00007. Anticancer Drugs. 2005. PMID: 15846117

2

Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B.

Guo XN, Zhong L, Zhang XH, Zhao WM, Zhang XW, Lin LP, Ding J. Guo XN, et al. Among authors: zhong l. Biochim Biophys Acta. 2004 Aug 4;1673(3):186-93. doi: 10.1016/j.bbagen.2004.04.015. Biochim Biophys Acta. 2004. PMID: 15279890

3

Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening.

Zhong L, Guo XN, Zhang XH, Wu ZX, Luo XM, Jiang HL, Lin LP, Zhang XW, Ding J. Zhong L, et al. Biochim Biophys Acta. 2005 Apr 15;1722(3):254-61. doi: 10.1016/j.bbagen.2004.12.015. Epub 2005 Jan 13. Biochim Biophys Acta. 2005. PMID: 15715968

4

In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine kinase inhibitor with anti-tumor and anti-angiogenic effects.

Guo XN, Zhong L, Tan JZ, Li J, Luo XM, Jiang HL, Nan FJ, Lin LP, Zhang XW, Ding J. Guo XN, et al. Among authors: zhong l. Cancer Biol Ther. 2005 Oct;4(10):1125-32. doi: 10.4161/cbt.4.10.2024. Epub 2005 Oct 15. Cancer Biol Ther. 2005. PMID: 16096368 Free article.

5

TKI-31 inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFRbeta.

Zhong L, Guo XN, Zhang XH, Sun QM, Tong LJ, Wu ZX, Luo XM, Jiang HL, Nan FJ, Zhang XW, Lin LP, Ding J. Zhong L, et al. Cancer Biol Ther. 2006 Mar;5(3):323-30. doi: 10.4161/cbt.5.3.2543. Epub 2006 Mar 23. Cancer Biol Ther. 2006. PMID: 16575201 Free article.

6

Establishment of the active catalytic domain of human PDGFRbeta tyrosine kinase-based ELISA assay for inhibitor screening.

Zhang XH, Guo XN, Zhong L, Luo XM, Jiang HL, Lin LP, Ding J. Zhang XH, et al. Among authors: zhong l. Biochim Biophys Acta. 2007 Oct;1770(10):1490-7. doi: 10.1016/j.bbagen.2007.06.017. Epub 2007 Jul 17. Biochim Biophys Acta. 2007. PMID: 17719179

7

Induction of leukemia cell apoptosis by cheliensisin A involves down-regulation of Bcl-2 expression.

Zhong L, Li CM, Hao XJ, Lou LG. Zhong L, et al. Acta Pharmacol Sin. 2005 May;26(5):623-8. doi: 10.1111/j.1745-7254.2005.00077.x. Acta Pharmacol Sin. 2005. PMID: 15842784

8

W2476 ameliorates β-cell dysfunction and exerts therapeutic effects in mouse models of diabetes via modulation of the thioredoxin-interacting protein signaling pathway.

Li T, Lin GY, Zhong L, Zhou Y, Wang J, Zhu Y, Feng Y, Cai XQ, Liu Q, Nosjean O, Boutin JA, Renard P, Yang DH, Wang MW. Li T, et al. Among authors: zhong l. Acta Pharmacol Sin. 2017 Jul;38(7):1024-1037. doi: 10.1038/aps.2017.15. Epub 2017 May 15. Acta Pharmacol Sin. 2017. PMID: 28502980 Free PMC article.

9

Adenine derivatives invert high glucose-induced thioredoxin-interacting protein overexpression.

Zhong L, Liu Q, Ting YS, Thien VY, Binti Kalong NS, Yang D, Wang MW. Zhong L, et al. Chem Biol Drug Des. 2018 Dec;92(6):1998-2008. doi: 10.1111/cbdd.13371. Epub 2018 Sep 11. Chem Biol Drug Des. 2018. PMID: 30043441

10

W2476 represses TXNIP transcription via dephosphorylation of FOXO1 at Ser319.

Zhong L, Liu Q, Liu Q, Zhang S, Cao Y, Yang D, Wang MW. Zhong L, et al. Chem Biol Drug Des. 2021 May;97(5):1089-1099. doi: 10.1111/cbdd.13828. Epub 2021 Feb 16. Chem Biol Drug Des. 2021. PMID: 33560565

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,253 results

Search Page

Filters